Marcin Nicoś1, Paweł Krawczyk2, Tomasz Powrózek2, Paulina Szudy2, Bożena Jarosz3, Marek Sawicki4, Justyna Szumiło5, Tomasz Trojanowski3, Janusz Milanowski2. 1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland marcin_nicos@interia.pl. 2. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland. 3. Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Lublin, Poland. 4. Department of Thoracic Surgery, Medical University of Lublin, Lublin, Poland. 5. Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland.
Abstract
BACKGROUND: In non-small cell lung cancer (NSCLC) the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene mutations have been reported in fewer than 5% of primary tumors. MATERIALS AND METHODS: We assessed PIK3CA gene mutations in 145 tissue samples from central nervous system (CNS) metastases of NSCLC using three polymerase chain reaction (PCR) techniques: high resolution melting-PCR (HRM-PCR), allele-specific-quantitative PCR (ASP-qPCR) and TaqMan PCR. RESULTS: HRM analysis allowed us to select three PIK3CA-positive specimens (2.1% of the studied group) and ASP-qPCR techniques identified them as one E542K and two H1047R substitutions, which were confirmed by TaqMan probes. The PIK3CA mutations were indicated only in males (3% of all males). One of the patients was reported to be a non-smoker with adenocarcinoma (AC; 2.5% of the AC group), however, the other two patients were smokers with squamous cell carcinoma (SCC; 3.4% of SCC group). CONCLUSION: This is the first report of the presence of PIK3CA gene mutation in CNS-metastatic lesions of NSCLC worldwide that could broaden therapeutic choices in such patients. Copyright
BACKGROUND: In non-small cell lung cancer (NSCLC) the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene mutations have been reported in fewer than 5% of primary tumors. MATERIALS AND METHODS: We assessed PIK3CA gene mutations in 145 tissue samples from central nervous system (CNS) metastases of NSCLC using three polymerase chain reaction (PCR) techniques: high resolution melting-PCR (HRM-PCR), allele-specific-quantitative PCR (ASP-qPCR) and TaqMan PCR. RESULTS: HRM analysis allowed us to select three PIK3CA-positive specimens (2.1% of the studied group) and ASP-qPCR techniques identified them as one E542K and two H1047R substitutions, which were confirmed by TaqMan probes. The PIK3CA mutations were indicated only in males (3% of all males). One of the patients was reported to be a non-smoker with adenocarcinoma (AC; 2.5% of the AC group), however, the other two patients were smokers with squamous cell carcinoma (SCC; 3.4% of SCC group). CONCLUSION: This is the first report of the presence of PIK3CA gene mutation in CNS-metastatic lesions of NSCLC worldwide that could broaden therapeutic choices in such patients. Copyright
Authors: Marcin Nicoś; Paweł Krawczyk; Bożena Jarosz; Marek Sawicki; Tomasz Trojanowski; Janusz Milanowski Journal: Brain Tumor Pathol Date: 2017-01-17 Impact factor: 3.298
Authors: Przemysław Kołodziej; Marcin Nicoś; Paweł A Krawczyk; Jacek Bogucki; Agnieszka Karczmarczyk; Daniel Zalewski; Tomasz Kubrak; Elżbieta Kołodziej; Anna Makuch-Kocka; Barbara Madej-Czerwonka; Bartosz J Płachno; Janusz Kocki; Anna Bogucka-Kocka Journal: Int J Mol Sci Date: 2021-02-19 Impact factor: 5.923